Biohaven Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 287.25K shares, a 2923.68% increase year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 18.93K shares, a 65.80% decline year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 56.91K shares, a 75.68% decline year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 17.46K shares, a 95.50% decline year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 139.23K shares, a 84.84% decline from fiscal 2024.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 918.16K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 287.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 380.55K shares derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 18.93K shares 10-Q · filed 2026-05-04 | 102.80K shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 56.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 139.23K shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 17.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 316.36K shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 9.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 687.14K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 55.37K shares 10-Q · filed 2025-05-12 | 715.54K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 234.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 918.16K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 388.23K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2024-06-30 | 37.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | |
| 2024-03-31 | 257.99K shares 10-Q · filed 2024-05-09 | |
| 2022-12-31 | 299.76K shares 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |